In 2019 Virginia completed her bachelor’s degree in biotechnology at the University of Siena with honors, discussing a thesis on a potential new universal flu vaccine. She then obtained a master’s degree in biomedical research from Imperial College in London (2019-2020). In the same year she started working at VisMederi, a company specializing in conducting serological assays for clinical trials; here she supervised projects on vaccines in development against yellow fever, SARS-CoV-2 and influenza viruses. In 2022 she began a work experience at GlaxoSmithKline (GSK) – Global Health, where she pursued a project on Klebsiella Pneumoniae, aimed at identifying capsular (K) and sub-capsular (O) antigens for vaccine development.

Since march 2023, she has joined Humanitas as a PhD student within prof. Garlanda’s group (Immunopathology laboratory). Her project is “Use of the RNA Technology for the therapy of infectious diseases based on humoral innate immunity molecules” and is funded by PNRR.